EUROPEAN RENAL ASSOCIATION - EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION    
 
Services How to use the platform Build a poster MANAGE ORDERS FAQs Contact HOMEPAGE
 
 
   
Discussion forum - 49th ERA-EDTA Congress
    Topic - Primary and secondary glomerulonephritis II

If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER.
 

Poster: 337
Visits: 629
Title: HIGH-DOSE IMMUNOSUPPRESSIVE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS WITH LUPUS NEPHRITIS: REMOTE OUTCOMES
Authors: Alexander Demin , V.A. Kozlov, I.A. Lisukov, O.S. Kotova, A.E. Sizikov, V.V. Sergeevicheva, L. M. Demina
Centre: Novosibirsk State Medical University

You must be registered to reply or comment.

HIGH-DOSE IMMUNOSUPPRESSIVE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS WITH LUPUS NEPHRITIS: REMOTE OUTCOMES

Alexander Demin
Thread initiator
Subspeciality
Reg: 4/21/2012 7:16:00 PM

 Comment# 1

I invite healthcare professionals to open debate around the issues raised in my poster, both those relating to research and to clinical practice.
Comment added on 4/21/2012 7:16:00 PM 
     
You must be registered to reply or comment.




Most viewed poster for this congress
Poster: 424
Visits: 2644
Title: Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Glomerulonephritides: an Immunohystochemical expression analysis
Authors: Giuseppe Coppolino ,
Centre: Chair of Nephrology, University Magna Graecia of Catanzaro, Catanzaro, Italy


Poster most viewed in this topic
Poster: 373
Visits: 964
Title: The efficacy and safety of Abelmoschus manihot (a traditional Chinese medicine) for chronic kidney disease: a systematic review and meta-analysis of observational studies
Authors: YIZHI CHEN ,
Centre: Division of Nephrology, Chinese Peoples Liberation Army (PLA) General Hospital


 View Poster Gallery
 Back to congress home
 Other Congresses


 
 
  About us  |  Terms and Conditions  |  Special Access